These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35355328)

  • 1. Editorial Comment to Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Miyata Y; Matsuo T
    Int J Urol; 2022 Jul; 29(7):655. PubMed ID: 35355328
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
    Niegisch G
    N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 5. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
    Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab Vedotin in Advanced Urothelial Carcinoma.
    Yeon SH; Lee HJ
    N Engl J Med; 2021 Jul; 385(1):93. PubMed ID: 34192440
    [No Abstract]   [Full Text] [Related]  

  • 11. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
    Petrylak DP; Powles T; Rosenberg JE
    N Engl J Med; 2021 Jul; 385(1):93-94. PubMed ID: 34192441
    [No Abstract]   [Full Text] [Related]  

  • 12. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
    J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
    Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
    Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Taguchi S
    Int J Urol; 2024 Apr; 31(4):348. PubMed ID: 38183313
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Bedke J; Maas M
    Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
    Azizi A; Houshyar R; Mar N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
    Moussa M; Papatsoris A; Abou Chakra M; Dellis A
    Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
    Ghatalia P; Plimack ER
    Nat Rev Clin Oncol; 2023 Dec; 20(12):818-819. PubMed ID: 37667009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.